Erste Group Bank Weighs in on Sandoz Group FY2026 Earnings

Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY) – Equities research analysts at Erste Group Bank issued their FY2026 earnings per share estimates for shares of Sandoz Group in a report issued on Thursday, August 27th. Erste Group Bank analyst H. Engel expects that the company will earn $4.10 per share for the year. Erste Group Bank currently has a “Strong-Buy” rating on the stock. The consensus estimate for Sandoz Group’s current full-year earnings is $4.11 per share. Erste Group Bank also issued estimates for Sandoz Group’s FY2027 earnings at $4.61 EPS.

Separately, Barclays upgraded shares of Sandoz Group from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. Four investment analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Strong Buy”.

Sandoz Group Price Performance

OTCMKTS SDZNY opened at $84.11 on Tuesday. Sandoz Group has a 52 week low of $55.42 and a 52 week high of $94.15. The company has a quick ratio of 0.77, a current ratio of 1.18 and a debt-to-equity ratio of 0.53. The firm’s 50-day simple moving average is $85.82 and its two-hundred day simple moving average is $83.78.

About Sandoz Group

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.